MILAN, Nov. 3 (Class Editori) – The entry of Chinese investments into our country has often been a concern. Yet there are many cases in which the acquisition of Italian companies by Chinese companies has given rise to interesting school cases, which should instead be studied carefully. One of which is precisely that of the NMS Group of Nerviano (just over 20 km from Milan), acquired 90% in March 2018 by the Chinese of Hefei Sari V-Capital Management, while 10% remained at the Regional Research Foundation Biomedical - Body of the Lombardy Region.
"The process of finding a partner wanted by the Fondazione immediately began not to speak Italian," said NMS president Andrea Agazzi, because since the beginning no major Italian group has come forward to express its interest in a reality which the whole world recognized as scientifically excellent. None of our operators seemed to have the will or the ability to face a sector with high returns, but which involves great risks and requires large amounts of capital. Instead, there have been numerous attentions and analyzes by both western and eastern international players, a sign of the fact that today oncology is really a globalized sector".
From what seemed a moment of impasse, then it tuned to a meeting between two different and complex cultures, as are the Italian and Chinese ones. "From this operation interesting opportunities were born for both", Agazzi confirms. "For us, an Italian company to enter the Chinese market, we will have more opportunities to attract researchers, important partnerships and to work on new drugs to be marketed in China. For our Chinese shareholders, at the same time, the opportunity to appear in the West, an action that has become increasingly difficult in recent years, following the restrictions set by Beijing and also the dispute on duties. All the more so in an important sector, such as pharmaceutical research". And in addition to the company, new incentives have also arrived for employees.
"Cohabitation is the most beautiful but also the most difficult part of the job", explains the president of Nms, "on the one hand there are always new and interesting ideas, on the other you must be able to collaborate having ways of working and relating very differently from each other". The new ownership confirmed the company line and introduced a Chinese management line in some sectors, such as oncology and clinical trial, where it was necessary to create value quickly. For the rest (from the president to the financial director, from the pre-clinical research to the production line) all the Italians remained at the desk.
Which have become faster and more flexible today. "This is a golden age for Italian pharmacological research, we produce exceptional resources and yet the big players all speak other languages." And that is why we must treasure what the contingent moment makes available and make it bear fruit. "Today we are bigger than we were before, with a capacity for developing drugs that puts us on an equal footing with other major competitors," emphasizes Agazzi, "we maintain Italian quality but with acceleration and power as only the Chinese can have it".
A great opportunity to bring more Italy to China, not only at the market level but also, for example, research thanks to the MoU signed with the Faculty of Pharmacy of Nanjing for the exchange of researchers between our two countries. And in the future of Nms there is also the listing on an important stock exchange, such as New York or Hong Kong. Because the market doesn't just live by numbers, says Agazzi, "but also about success stories".
(Source:Class Editori)
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
